MiR‐291a‐3p regulates the BMSCs differentiation via targeting DKK1 in dexamethasone‐induced osteoporosis

Abstract

Abstract Osteoporosis is a skeleton disease affecting 55% of people over age 60, and the number is still increasing due to an ageing population. One method to prevent osteoporosis is to increase the formation of new bone while preventing the resorption of older bone. Thus, osteogenic differentiation of bone marrow‐derived mesenchymal stem cells (BMSCs) is of great importance in improving the treatment of osteoporosis. On the other hand, glucocorticoids (GCs) are widely used to treat the chronic inflammatory disorders, but long‐term exposure to GCs can induce osteoporosis. In present study, we treated BMSCs with dexamethasone (DEX) to simulate GC‐induced osteoporosis. MTT assay, ALP activity, and Alizarin Red were used to evaluate the role miRNA‐291a‐3p in the DEX‐induced osteogenic differentiation suppression. Further, we used qPCR and western blot to investigate the mechanisms of miRNA‐291a‐3p affecting BMSCs differentiation. The results showed that miRNA‐291a‐3p could improve the cell viability, osteogenic differentiation, and ALP activity, which are suppressed by DEX in BMSCs. Furthermore, we found that the osteogenesis genes Runx2, DMP1, and ALP were upregulated whereas the lipogenic genes C/EBPα and PPARγ were downregulated when miRNA‐291a‐3p mimics were transfected. Additionally, we demonstrated that miRNA‐291a‐3p promoted BMSCs' osteogenic differentiation by directly suppressing DKK1 mRNA and protein expression and subsequently activating Wnt/β‐catenin signaling pathway. Our study suggests that miR‐291a‐3p plays an important role in preventing osteoporosis and may serve as a potential miRNA osteoporosis biomarker.

Keywords

• BMSCs
• DEX
• DKK1
• miR‐291a‐3p
• osteogenic differentiation